Guangzhou Innogen Pharmaceutical (HKG:2591) submitted a filing application for the proposed conversion of all its domestic unlisted shares into Hong Kong-listed shares to the China Securities Regulatory Commission, a Tuesday Hong Kong bourse filing said.
The firm also intends to apply for the listing of, and permission to deal in, the converted shares on the Main Board of the Hong Kong Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments